ERBB2 and breast carcinoma: Here, we demonstrate the sensitivity of our approach by quantifying kinase activation states in a Her2+ breast cancer patient, analyzing tissue material obtained from half a 14G needle biopsy taken prior to treatment (Figure 3D).